EGFR 基因状态对晚期非小细胞肺癌一线化疗的影响

目的：评价 EGFR 突变状态对晚期非小细胞肺癌（NSCLC）一线化疗近期疗效、无疾病进展时间（PFS）的影响。方法：同期非随机对照研究，依照入选标准，入组67例初治晚期 NSCLC EGFR 野生型患者及51例初治晚期 NSCLC EGFR 敏感突变型患者，分别观察客观有效率（RR）、疾病控制率（DCR）及无疾病进展时间（PFS）。结果：EGFR 野生型与 EGFR 敏感突变型的晚期 NSCLC 一线化疗的近期有效率分别为16．4％和28．6％，差异无统计学意义（P ＞0．05），疾病控制率分别为61．2％和81．6％，差异有统计学意义（P ＜0．05）。PFS 分别为3个月与5个月，差异有统计学意义（P ＜0．05）。结论：化疗仍然是 EGFR 敏感突变型的晚期NSCLC 一线治疗的重要选择，在 DCR 及 PFS 方面，明显优于 EGFR 野生型晚期 NSCLC。

Influence of EGFR statuses on first -line chemotherapy in patients with advanced non -small cell lung cancer

Objective:To evaluate whether EGFR mutation affects the outcome of first -line chemotherapy of late stage NSCLC patients.Methods:All 67 EGFR wild type and 51 EGFR -mutated NSCLC patients in the late stages were enrolled in our cohort study.The response rate(RR),disease control rate(DCR)and progression -free survival (PFS)among the patients were analyzed.Results:The RR for first -line hemotherapy of patients with EGFR wild type and mutation was 16.4% and 28.6%,respectively(P >0.05).The DCR was 61.2% in the wild type EGFR co-hort and 81.6% in the mutant EGFR patients(P <0.05).The PFS of the mutant EGFR cases was better than wild type EGFR cases(5 months vs 3 months,P <0.05).Conclusion:First -line chemotherapy is highly effective against mutated -EGFR advanced NSCLC compared with wild type EGFR.